Navigation Links
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Date:8/19/2007

LYON, France, Aug. 17 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, is currently conducting clinical investigations in France under an approved clinical trial combining the company's Ablatherm-HIFU device with chemotherapy using docetaxel.

The study is a primary treatment therapy program for men suffering from clinically localized but aggressive high risk prostate cancer typically classified as stage T2c. The study began in late 2006 and will enroll a total of 30 men, of which more than 10 have already been treated.

"Combination therapy is well documented as a treatment protocol for men suffering more aggressive prostate cancers," said Dr. Albert Gelet, Edouard Herriot Hospital, Lyon. "Ablatherm-HIFU is a proven effective treatment for localized prostate cancer already with strong clinical support. This study aims to evaluate its use under an additional dedicated protocol for men in the T2c cancer stage where the tumors are known to be more aggressive, creating a higher risk of relapse if the patient is treated with only a localized therapy. It was demonstrated in pre-clinical studies that HIFU improves chemotherapy drug efficacy in the area around burned tissues."

Under the approved protocol by French Ethical Committee, patients are administered a dose of docetaxel 30 minutes prior to a standard primary indication HIFU session lasting an average of two hours. The Ablatherm-HIFU ablates the prostate tissue according to conventional procedures and protocols. All treatments are administered at Edouard Herriot Hospital in Lyon, France.

"EDAP has a strong scientific and clinical base underlying the Ablatherm-HIFU, with constant work to enhance and extend the capabilities of the device," said Pr John Rewcastle, Medical Director for EDAP. "With already well documented specialized protocols for primary therapy, HIFU retreatment and salvage th
'/>"/>

SOURCE EDAP TMS S.A.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Object recognition technology has a unique and ... The VelaSense ® mobile platform incorporates ... productive and fulfilling lives. VelaSense ® will now ... identify objects from a one million object database, that ... databases for personal use. Visus Technology ...
(Date:3/27/2015)... Dynatronics Corporation (NASDAQ: DYNT ) today announced ... the Company,s Board of Directors effective March 23, 2015, to ... of board member Joseph Barton .  ... of Directors represents an important step forward for the company," ... Dynatronics.  "Rich is a proven leader and is well-known for ...
(Date:3/27/2015)... AUGUSTA, Ga. , March 27, 2015  Holographic ... innovator in the field of holographic medical imaging, is ... of its Kickstarter campaign. Launching on April 20 th ... Voxbox and Voxbox Pro. The 8-inch and 22-inch displays ... at home for the first time. In addition to ...
Breaking Medicine Technology:VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... Pfizer announced today,that Lipitor (atorvastatin calcium) Tablets 80 ... events and major coronary events,in type 2 diabetes ... who had experienced a recent stroke or mini-stroke, ... analysis of the landmark,Stroke Prevention by Aggressive Reduction ...
... 2007 /PRNewswire/ -- Novagali Pharma, an,emerging pharmaceutical company ... phase III clinical trial,positive results from the Phase ... Vernal Keratoconjunctivitis (VKC) at the,XIV Afro-Asian Congress of ... in Marrakech (Morocco). , VKC is a severe ...
Cached Medicine Technology:Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 2Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
(Date:3/29/2015)... York, NY (PRWEB) March 29, 2015 ... that conduct clinical trials and research, manage data ... to help their clients reach regulation standards. Contract ... pharmaceutical and medical device manufacturing sectors. Industry operators ... from early- to late-stage clinical research for Food ...
(Date:3/29/2015)... PORTLAND, Ore. (PRWEB) March 29, 2015 ... and Marion counties in Oregon to assess the feasibility ... youth with emotional and behavioral problems and their families. ... competition to select participants that will be provided technical ... The Oregon counties join six other national awardees chosen ...
(Date:3/29/2015)... IL (PRWEB) March 29, 2015 “Health ... Brickner, “and as we learn more about the cannabinoid ... In March Homeostasis: Publius’ Go Endo-Cannabinoid Update ... health, or endo-healing, is celebrated. Publius, of The Cannabis ... 2015 National Institutes of Health (PubMed) cannabinoid system (CS) ...
(Date:3/28/2015)... Tucson, AZ. (PRWEB) March 28, 2015 ... according to a new study by researchers ... (HSPH). , Produced with the support of the Coffee ... the journal Molecular Psychiatry this past fall, the study—one ... a meta-analysis of genomic data from more than 120,000 ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
Breaking Medicine News(10 mins):Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2
... Telesso Technologies Limited, a global healthcare company, announced ... site to enroll patients in a head-to-head trial ... versus the industry,s gold standard device for peripheral ... trial with Vascular Pathways, Inc. 
 

 , ...
... Mass., April 22 Sabertec , an ... , a device designed to reduce CO2 emissions and ... tailpipes while increasing fuel efficiency, took part in a press ... MA Mayor James E. Harrington .At the press conference, ...
... Earnings per Share -- Announces the Acquisition of Cervitech(R) ... up 56.3% from the first quarter 2008 and up ... 81.5% compared to 82.2% for first quarter 2008- GAAP ... of $(0.27) - $(0.25)- First quarter loss per share ...
... and meds could put many at disadvantage, study suggests ... patients may have more difficulty getting dialysis under a ... for Medicare & Medicaid Services will make a single ... injectable medications. These services were previously reimbursed separately. , ...
... boost the ranks of the uninsured , , WEDNESDAY, April 22 ... insurance for a period of time is greater today than ... , These gaps in coverage, however, are shorter than they ... programs, such as Medicaid. , "The bad news is the ...
... IRVINE and DOWNEY, Calif., April 22 Downey ... to outsource its patient financial services to Cymetrix. ... will manage all operations of the DRMC patient ... resolution, from its Los Angeles Business Processing Center.With ...
Cached Medicine News:Health News:Telesso initiates post-market head-to-head peripheral IV catheter study 2Health News:Brockton Mayor, James E. Harrington Calls Press Conference to Unveil Newly Adopted Auto Emissions Technology Acquired With Federal Stimulus Money 2Health News:Brockton Mayor, James E. Harrington Calls Press Conference to Unveil Newly Adopted Auto Emissions Technology Acquired With Federal Stimulus Money 3Health News:NuVasive Reports First Quarter 2009 Financial Results 2Health News:NuVasive Reports First Quarter 2009 Financial Results 3Health News:NuVasive Reports First Quarter 2009 Financial Results 4Health News:NuVasive Reports First Quarter 2009 Financial Results 5Health News:NuVasive Reports First Quarter 2009 Financial Results 6Health News:NuVasive Reports First Quarter 2009 Financial Results 7Health News:NuVasive Reports First Quarter 2009 Financial Results 8Health News:NuVasive Reports First Quarter 2009 Financial Results 9Health News:NuVasive Reports First Quarter 2009 Financial Results 10Health News:NuVasive Reports First Quarter 2009 Financial Results 11Health News:NuVasive Reports First Quarter 2009 Financial Results 12Health News:NuVasive Reports First Quarter 2009 Financial Results 13Health News:NuVasive Reports First Quarter 2009 Financial Results 14Health News:More Americans Experiencing Gaps in Health Coverage 2Health News:More Americans Experiencing Gaps in Health Coverage 3Health News:Downey Regional Medical Center Partners With Cymetrix to Implement Revenue Cycle Solutions 2
... Reichert MK1 Keratometer now utilizes ... consistent lighting, removing the need ... we didnt change are all ... made our Keratometer the worldwide ...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
Inquire...
Medicine Products: